Visual Telerehabilitation in Children, Adolescents and Young Adults With Hemianopsia Consecutive to a Brain Tumour

NANot yet recruitingINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

June 1, 2024

Primary Completion Date

June 1, 2027

Study Completion Date

June 1, 2027

Conditions
Hemianopsia
Interventions
DEVICE

Audiovisual stimulation

The MOT IVR audiovisual stimulation task involves the 3D multiple-object-tracking paradigm composed of 6-8 high-contrast spheres which features are adapted to the visual ability of individuals with low-vision (luminosity = 80 nits, size = 1° to 3° visual angle). The spheres move for 20s. following random linear paths, bouncing on one another and on the walls of a virtual 3D cube when collisions occur. The participant, comfortably seated, is asked to track the moving cued target among moving distractors for 20s. A spatial sound is correlated to the movement of the cued target. After 20s., the movement stops and the participant is asked to select, using a laser pointer, the cued sphere among the distractors (mark-all procedure). Speed of the spheres is regulated by a staircase 1:1 procedure. The stimulation can here be stopped by the participant if required. After 3 blocks of 15x20s., the system stops and goes on stand-by mode until the next session. Data are collected in real time.

Trial Locations (5)

T3B 6A8

Alberta Children's Hospital, Calgary

V6H 3N1

British Columbia Children's Hospital, Vancouver

M5G 1E8

The Hospital for Sick Children, Toronto

H3T 1C5

Centre Hospitalier Universitaire Sainte-Justine, Montreal

G1J 1Z4

CHU de Québec, Québec

All Listed Sponsors
collaborator

Alberta Children's Hospital

OTHER

collaborator

St. Justine's Hospital

OTHER

collaborator

The Hospital for Sick Children

OTHER

collaborator

British Columbia Children's Hospital

OTHER

lead

University Health Network, Toronto

OTHER

NCT06362434 - Visual Telerehabilitation in Children, Adolescents and Young Adults With Hemianopsia Consecutive to a Brain Tumour | Biotech Hunter | Biotech Hunter